LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday that its once-weekly type 2 diabetes treatment Tanzeum is now available in US pharmacies.
Glaxo said that it is committed to taking a responsible approach to pricing, and that Tanzeum has been priced in line with this commitment.
Tanzeum was approved by the US Food and Drug Administration April 15. It is not recommended as a first line therapy for patients whose diabetes is inadequately controlled by diet and exercise.
Shares in GlaxoSmithKline were trading up 0.9% at 1,426.50 pence Tuesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
